Table 1.

Covariates used in the two-stage and inverse probability of censoring weights methods

Covariates
Baseline covariates:
Age (years, continuous)
Time since diagnosis (categorical; <5 vs. ≥5 years)
Number of bone metastases at screening (categorical; ≤5 vs. >5)
Presence of visceral disease at baseline (categorical; yes vs. no)
Type of disease progression at study entry (categorical; PSA progression only vs. radiographic progression with or without PSA vs. no disease progression at study entry)
Baseline EQ-5D utility index (continuous)
Baseline FACT-P total score (continuous)
Secondary baseline covariates:
ECOG Performance Status at secondary baseline (categorical; 0 vs. otherwise)
Occurrence of grade 3–5 adverse events at secondary baseline (categorical; yes vs. no)
Occurrence of grade 3–5 adverse events prior to the secondary baseline (categorical; yes vs. no)
Corticosteroid use at secondary baseline (categorical; yes vs. no)
PSA level at secondary baseline (continuous)
Laboratory tests: LDH level at secondary baseline (categorical; ≤240 IU/mL vs. >240 IU/mL)
EQ-5D utility index at secondary baseline (continuous)
FACT-P total score at secondary baseline (continuous)
Time to treatment discontinuation (continuous)
Disease progression (categorical; yes vs. no)
Switching indicator (yes vs. no)

ECOG Eastern Cooperative Oncology Group, FACT-P Functional Assessment of Cancer Therapy–Prostate, LDH lactate dehydrogenase, PSA prostate-specific antigen